Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists

- Glewis, Sarah, Lingaratnam, Senthil, Krishnasamy, Michael, Martin, Jennifer H., Tie, Jeanne, Alexander, Marliese, Michael, Michael

Enhanced degradation mechanism of anticancer drug irinotecan through low-frequency ultrasound assisted reactive electrochemical membrane

- Meng, Xinxin, Liu, Zhun, Qian, Xubin, Tang, Shaoyu, Fang, Cheng, Niu, Junfeng, Xu, Lei

Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites

- Liu, Zheng, Martin, Jennifer H., Hatzimihalis, Athena, Campbell, Ian, Crowley, Simone, Beale, Phillip J., Karapetis, Christos S., Price, Timothy, Burge, Mathew E., Michael, Michael, Liauw, Winston, Mclachlan, Sue-Anne, Link, Emma, Matera, Anetta, Thompson, Michael, Jefford, Michael, Hicks, Rod J., Cullinane, Carleen

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

- Shapiro, Jeremy D., Thavaneswaran, Subotheni, Tebbutt, Niall C., Price, Timothy J., Khasraw, Mustafa, Van Hazel, Guy A., Waring, Paul M., Tejpar, Sabine, Simes, John, Gebski, Val J., Desai, Jayesh, Segelov, Eva, Underhill, Craig R., Robledo, Kristy P., Karapetis, Chistos S., Day, Fiona L., Nott, Louise M., Jefford, Michael, Chantrill, Lorraine A., Pavlakis, Nick

Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE Study

- Lim, Robert, Sun, Yan, Im, Seock-Ah, Hsieh, Ruey-Kuen, Yau, Tsz Kok, Bonaventura, Anthony, Cheirsilpa, Arkom, Esser, Regina, Mueser, Matthias, Advani, Suresh